Cytokinetics director sells $72K in stock

CYTOKINETICS director Robert E. Landry sold 1,000 CYTK shares under a Rule 10b5-1 trading plan, leaving him with 8,184 shares.

Rhea-AI Filing Summary

CYTOKINETICS INC (CYTK) director Robert E. Landry reported selling 1,000 shares of Common Stock on September 15, 2026 in an open market or private transaction at $72.13 per share. After this sale, he directly holds 8,184 shares of CYTK common stock. The filing affirms use of a Rule 10b5-1 trading plan.

Insider Trade Summary 10b5-1

Net Seller: 1,000 shares

Net Sell 1 txn

Insider Landry Robert E

Role Director

Sold 1,000 shs ($72K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,000	$72.13	$72K

Holdings After Transaction: Common Stock — 8,184 shares (Direct)

Key Figures

Shares sold: 1,000 shares Sale price per share: $72.13 per share Transaction value: $72,130 +1 more

4 metrics

Shares sold 1,000 shares Common Stock sale reported for September 15, 2026

Sale price per share $72.13 per share Open market or private transaction on September 15, 2026

Transaction value $72,130 1,000 shares sold at $72.13 per share

Shares held after transaction 8,184 shares Direct holdings after the reported sale

Key Terms

Rule 10b5-1 trading plan, Common Stock, open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"The filing affirms use of a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Common Stock financial

"reported selling 1,000 shares of Common Stock on September 15, 2026"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open market or private transaction financial

"Sale in open market or private transaction at $72.13 per share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CYTK director Robert E. Landry report?

Robert E. Landry reported a sale of 1,000 shares of CYTOKINETICS INC Common Stock on September 15, 2026 in an open market or private transaction at $72.13 per share.

How many CYTK shares does Robert E. Landry hold after this Form 4 transaction?

After the reported sale, Robert E. Landry directly holds 8,184 shares of CYTOKINETICS INC Common Stock.

Was Robert E. Landry’s CYTK stock sale made under a Rule 10b5-1 plan?

Yes. The filing affirms that the reported transactions were made under a Rule 10b5-1 trading plan, indicating they were pre-arranged under that rule.

What price did Robert E. Landry receive per CYTK share in this sale?

He sold the 1,000 CYTOKINETICS INC shares at a reported price of $72.13 per share in an open market or private transaction.

What is the approximate dollar value of Robert E. Landry’s CYTK stock sale?

Based on 1,000 shares sold at $72.13 per share, the reported transaction value is approximately $72,130.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 05:23 PM Accepted by SEC EDGAR 09/15/2026 - 05:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Landry Robert E

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94580

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2026		S		1,000	D	$72.13	8,184	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Mr. Landry	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)